Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th/To autoantigen

Autoimmunity Reviews

Volumn 14, Issue 3, 2015, Pages 254-257

  Mahler, Michael ^a   Fritzler, Marvin J ^b   Satoh, Minoru ^c  

^a INOVA DIAGNOSTICS INC   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; EPITOPE; MITOCHONDRIAL RNA; MITOCHONDRIAL RNA PROCESSING COMPLEX; MITOCHONDRIAL RNA PROCESSING COMPLEX ANTIBODY; RIBONUCLEASE P; TH ANTIGEN; TO ANTIGEN; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; RNA; RNA, MITOCHONDRIAL; TO AUTOANTIGEN;

ALGORITHM; ANTIBODY DETECTION; CHEMOLUMINESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; IMMUNOASSAY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MIXED CONNECTIVE TISSUE DISEASE; MYOPATHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; HELPER CELL; IMMUNOLOGY;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; HUMANS; RNA; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84920973344     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.11.007     Document Type: Review

References (36)

1. Mahler M., Fritzler M.J. Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci 2010, 1183:267-287.
2. Mehra S., Walker J., Patterson K., et al. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12:340-354.
3. Satoh M., Vazquez-Del Mercado M., Chan E.K. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009, 19:219-228.
4. Mahler M., Fritzler M.J. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol 2012, 2012:494356.
5. Satoh M., Chan E.K., Ho L.A., et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012, 64:2319-2327.
6. Walker U.A., Tyndall A., Czirjak L., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763.
7. Mahler M., Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007, 6:432-437.
8. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
9. Arnett F.C., Reveille J.D., Goldstein R., et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996, 39:1151-1160.
10. Ceribelli A., Cavazzana I., Franceschini F., et al. Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 2010, 37:2071-2075.
11. Van Eenennaam H., Vogelzangs J.H., Lugtenberg D., et al. Identity of the RNase MRP- and RNase P-associated Th/To autoantigen. Arthritis Rheum 2002, 46:3266-3272.
12. Van Eenennaam H., Vogelzangs J.H., Bisschops L., et al. Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 2002, 130:532-540.
13. Okano Y., Medsger T.A. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990, 33:1822-1828.
14. Fischer A., Pfalzgraf F.J., Feghali-Bostwick C.A., et al. Anti-Th/To-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006, 33:1600-1605.
15. Wiik A.S., Hoier-Madsen M., Forslid J., et al. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010, 35:276-290.
16. Kuwana M., Kimura K., Hirakata M., et al. Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 2002, 61:842-846.
17. Mahler M., Gascon C., Patel S., et al. Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Res Ther 2013, 15:R50.
18. Mahler M., Satoh M., Hudson M., et al. Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. J Rheumatol 2014, 41:1334-1343.
19. Villalta D., Imbastaro T., Di Giovanni S., et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012, 12:114-120.
20. Bonroy C., Van Praet J., Smith V., et al. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods 2012, 379:53-60.
21. Ceribelli A., Satoh M., Chan E.K. A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis. Arthritis Res Ther 2012, 14:R128.
22. Krzyszczak M.E., Li Y., Ross S.J., et al. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 2011, 30:1333-1339.
23. Hudson M., Satoh M., Chan J.Y., et al. Prevalence and clinical profiles of "autoantibody-negative" systemic sclerosis subjects. Clin Rheumatol 2013, 86:127-136.
24. Bluthner M., Mahler M., Muller D.B., et al. Identification of an alpha-helical epitope region on the PM/Scl-100 autoantigen with structural homology to a region on the heterochromatin p25beta autoantigen using immobilized overlapping synthetic peptides. J Mol Med (Berl) 2000, 78:47-54.
25. Mahler M., Maes L., Blockmans D., et al. Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther 2010, 12:R99.
26. Mahler M., Raijmakers R., Dahnrich C., et al. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther 2005, 7:R704-R713.
27. Graf S.W., Hakendorf P., Lester S., et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012, 15:102-109.
28. Mierau R., Moinzadeh P., Riemekasten G., et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011, 13:R172.
29. Koenig M., Fritzler M.J., Targoff I.N., et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007, 9:R78.
30. Mitri G.M., Lucas M., Fertig N., et al. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003, 48:203-209.
31. Walker J.G., Fritzler M.J. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007, 19:580-591.
32. Koenig M., Joyal F., Fritzler M.J., et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008, 58:3902-3912.
33. Rossi D., Russo A., Manna E., et al. The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev 2013, 12:821-825.
34. Pope J., Harding S., Khimdas S., et al. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. J Rheumatol 2012, 39:524-531.
35. Meier F.M., Frommer K.W., Dinser R., et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012, 71:1355-1360.
36. Nikpour M., Hissaria P., Byron J., et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011, 13:R211.